Compare LYTS & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LYTS | CRVS |
|---|---|---|
| Founded | 1976 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 925.2M | 1.1B |
| IPO Year | 1994 | 2016 |
| Metric | LYTS | CRVS |
|---|---|---|
| Price | $25.59 | $15.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $27.50 | ★ $30.17 |
| AVG Volume (30 Days) | 494.6K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $573,377,000.00 | N/A |
| Revenue This Year | $16.20 | N/A |
| Revenue Next Year | $27.71 | N/A |
| P/E Ratio | $53.31 | ★ N/A |
| Revenue Growth | ★ 22.09 | N/A |
| 52 Week Low | $17.21 | $3.79 |
| 52 Week High | $27.36 | $26.95 |
| Indicator | LYTS | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 71.49 |
| Support Level | $21.96 | $14.24 |
| Resistance Level | $27.36 | $16.85 |
| Average True Range (ATR) | 1.09 | 0.79 |
| MACD | -0.04 | 0.45 |
| Stochastic Oscillator | 38.11 | 85.55 |
LSI Industries Inc provides corporate visual image solutions to the petroleum and convenience store industry. The company's operating segments include Lighting and Display Solutions. It generates maximum revenue from the Display solutions segment. Lighting Segment manufactures and markets outdoor and indoor lighting and lighting controls for the commercial, industrial, and multi-site retail markets, including the petroleum/convenience store, quick-service, and automotive markets. The Display Solutions Segment manufactures, sells, and installs exterior and interior visual image and display elements, including printed graphics, structural graphics, digital signage, menu board systems, display fixtures, refrigerated displays, and custom display elements.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.